Company news

Rapport Therapeutics, Inc. (NASDAQ:RAPP) news

Every Rapport Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Rapport Therapeutics, Inc. stock analysis →

Press releases & updates

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

August 24, 2026

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

August 5, 2026

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

May 7, 2026

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at ...

April 21, 2026

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of ...

April 1, 2026

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 10, 2026

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in G...

March 9, 2026

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress...

January 7, 2026

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response ...

December 5, 2025

Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilep...

November 25, 2025

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

November 6, 2025

Rapport Therapeutics to Participate in Upcoming Investor Conferences

November 5, 2025

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 11, 2025

Rapport Announces Pricing of Public Offering of Common Stock

September 9, 2025

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

September 8, 2025

Rapport Announces Proposed Public Offering of Common Stock

September 8, 2025

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

September 5, 2025

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

August 7, 2025

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

June 2, 2025

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025

Rapport Therapeutics to Host 2025 Investor and Analyst Day

May 21, 2025

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

May 8, 2025

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

March 21, 2025

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 11, 2025

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medic...

March 3, 2025

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

January 9, 2025

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Re...

December 6, 2024

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

November 14, 2024

Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

November 7, 2024

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

November 4, 2024

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

September 5, 2024

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in ...

August 29, 2024

Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update

August 8, 2024

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

July 29, 2024

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purcha...

June 12, 2024